The Korean Journal of Physiology and Pharmacology

  • 제14권6호
  • /
  • Pages.391-397
  • /
  • 2010
  • /
  • 1226-4512(pISSN)
  • /
  • 2093-3827(eISSN)
대한약리학회 (The Korean Society of Pharmacology)
권호 표지
DOI QR코드

DOI QR Code

Curcumin Induces Downregulation of E2F4 Expression and Apoptotic Cell Death in H CT116 Human Colon Cancer Cells; Involvement of Reactive Oxygen Species

  • Kim, Kyung-Chan (Department of Internal Medicine, College of Medicine, Catholic University of Daegu) ;
  • Lee, Chu-Hee (Department of Biochemistry and Molecular Biology, School of Medicine, Yeungnam University)
  • 투고 : 2010.10.18
  • 심사 : 2010.12.10
  • 발행 : 2010.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

E2F transcription factors and their target genes have been known to play an important role in cell growth control. We found that curcumin, a polyphenolic phytochemical isolated from the plant Curcuma longa, markedly suppressed E2F4 expression in HCT116 colon cancer cells. Hydrogen peroxide was also found to decrease E2F4 protein level, indicating the involvement of reactive oxygen species (ROS) in curucmin-induced downregulation of E2F4 expression. Involvement of ROS in E2F4 downregulation in response to curcumin was confirmed by the result that pretreatment of cells with N-acetylcystein (NAC) before exposure of curcumin almost completely blocked the reduction of E2F4 expression at the protein as well as mRNA level. Anti-proliferative effect of curcumin was also suppressed by NAC which is consistent to previous reports showing curcumin-superoxide production and induction of poly (ADP-ribose) polymerase (PARP) cleavage as well as apoptosis. Expression of several genes, cyclin A, p21, and p27, which has been shown to be regulated in E2F4-dependent manner and involved in the cell cycle progression was also affected by curcumin. Moreover, decreased (cyclin A) and increased (p21 and p27) expression of these E2F4 downstream genes by curcumin was restored by pretreatment of cells with NAC and E2F4 overexpression which is induced by doxycycline. In addition, E2F4 overexpression was observed to partially ameliorate curcumin-induced growth inhibition by cell viability assay. Taken together, we found curcumin-induced ROS down-regulation of E2F4 expression and modulation of E2F4 target genes which finally lead to the apoptotic cell death in HCT116 colon cancer cells, suggesting that E2F4 appears to be a novel determinant of curcumin-induced cytotoxicity.

키워드

참고문헌

  1. Bandara LR, La Thangue NB. Adenovirus E1a prevents the retinoblastoma gene product from complexing with a cellular transcription factor. Nature. 1991;351:494-497. https://doi.org/10.1038/351494a0
  2. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell. 1991;65:1053-1061. https://doi.org/10.1016/0092-8674(91)90557-F
  3. Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L, Miron A, Nevins JR. Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins. Mol Cell Biol. 2000;20:3626-3632. https://doi.org/10.1128/MCB.20.10.3626-3632.2000
  4. He Y, Armanious MK, Thomas MJ, Cress WD. Identification of E2F-3B, an alternative form of E2F-3 lacking a conserved N-terminal region. Oncogene. 2000;19:3422-3438. https://doi.org/10.1038/sj.onc.1203682
  5. DeGregori J, Johnson DG. Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis. Curr Mol Med. 2006;6:739-748.
  6. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 1993;365:349-352. https://doi.org/10.1038/365349a0
  7. Markel M, Wenkel J, Bannister AJ, Kouzarides T, Hagemeier C. An E2F-like repressor of transcription. Nature. 1997;390:567-568. https://doi.org/10.1038/37507
  8. Cartwright P, Muller H, Wagener C, HoIm K, Helin K. E2F-6: a novel member of the E2F family is an inhibitor of E2F-dependent transcription. Oncogene. 1998;17:611-623. https://doi.org/10.1038/sj.onc.1201975
  9. Trimarchi JM, Fairchild B, Verona R, Moberg K, Andon N, Lees JA. E2F-6, a member of the E2F family that can behave as a transcriptional repressor. Proc Natl Acad Sci USA. 1998;95:2850-2855. https://doi.org/10.1073/pnas.95.6.2850
  10. Koziczak M, Krek W, Nagamine Y. Pocket protein-independent repression of urokinase-type plasminogen activator and plasminogen activator inhibitor 1 gene expression by E2F1. Mol Cell Biol. 2000;20:2014-2022. https://doi.org/10.1128/MCB.20.6.2014-2022.2000
  11. Garneau H, Paquin MC, Carrier JC, Rivard N. E2F4 expression is required for cell cycle progression of normal intestinal crypt cells and colorectal cancer cells. J Cell Physiol. 2009;221:350-358. https://doi.org/10.1002/jcp.21859
  12. Abe Y, Hashimoto S, Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res. 1999;39:41-47. https://doi.org/10.1006/phrs.1998.0404
  13. Oyama Y, Masuda T, Nakata M, Chikahisa L, Yamazaki Y, Miura K, Okagawa M. Protective actions of 5'-n-alkylated curcumins on living cells suffering from oxidative stress. Eur J Pharmacol. 1998;360:65-71. https://doi.org/10.1016/S0014-2999(98)00635-9
  14. Nagano T, Oyama Y, Kajita N, Chikahisa L, Nakata M, Okazaki E, Masuda T. New curcuminoids isolated from Zingiber cassumunar protect cells suffering from oxidative stress: a flow-cytometric study using rat thymocytes and H2O2. Jpn J Pharmacol. 1997;75:363-370. https://doi.org/10.1254/jjp.75.363
  15. Cho Jy, Kang PJ, Chun W, Moon YO, Park YT, Lim SY, Kim SS. Curcumin attenuates glial cell activation but cannot suppress hippocampal CA3 neuronal cell death in i.c.v. Kanic Acid Injection Model. Korean J Physiol Pharmacol. 2003;7:307-310.
  16. Kong PJ, Kwon OY, Han YH, Kim SY, Lee SN, Son HJ, Kim SS. Comparison of Inhibitory Potency of Various Antioxidants on the Activation of BV2 Microglial Cell Lines Induced by LPS. Korean J Physiol Pharmacol. 2007;11:9-13.
  17. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res. 2001;21:2895-2900.
  18. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plunnner SM, Pirmohamed M, Gescher AJ, Steward WP. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10:6847-6854. https://doi.org/10.1158/1078-0432.CCR-04-0744
  19. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14:4491-4499. https://doi.org/10.1158/1078-0432.CCR-08-0024
  20. Watson JL, Hill R, Yaffe PB, Greenshields A, Walsh M, Lee PW, Giacomantonio CA, Hoskin DW. Curcumin causes super-oxide anion production and p53-independent apoptosis in human colon cancer cells. Cancer Lett. 2010;297:1-8. https://doi.org/10.1016/j.canlet.2010.04.018
  21. Moragoda L, Jaszewski R. Majumdar AP. Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res. 2001;21:873-878.
  22. Lee DH, Choi HC, Lee KY, Kang YJ. Aprotinin Inhibits Vascular Smooth Muscle Cell Inflammation and Proliferation via Induction of HO-1. Korean J Physiol Pharmacol. 2009;13:123-129. https://doi.org/10.4196/kjpp.2009.13.2.123
  23. Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol. 2007;595:105-125. https://doi.org/10.1007/978-0-387-46401-5_3
  24. Woo JH, Kim YH, Choi YJ, Kim DG, Lee KS, Bae JH, Min DS, Chang JS, Jeong YJ, Lee YH, Park JW, Kwon TK. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis. 2003;24:1199-1208. https://doi.org/10.1093/carcin/bgg082
  25. Muller H, Bracken AP, Yemen R. Moroni MC, Christians F, Grassilli E, Prosperini E, Vigo E, Oliner JD, Helin K E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev. 2001;15:267-285. https://doi.org/10.1101/gad.864201
  26. Young AP, Nagarajan R, Longmore GD. Mechanisms of transcriptional regulation by Rb-E2F segregate by biological pathway. Oncogene. 2003;22:7209-7217. https://doi.org/10.1038/sj.onc.1206804
  27. Polager S, Kalma Y, Berkovich E, Ginsberg D. E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis. Oncogene. 2002;21:437-446. https://doi.org/10.1038/sj.onc.1205102
  28. DuPree EL, Mazumder S, Almasan A. Genotoxic stress induces expression of E2F4, leading to its association with p130 in prostate carcinoma cells. Cancer Res. 2004;64:4390-4393. https://doi.org/10.1158/0008-5472.CAN-03-3695

피인용 문헌

  1. Prevention and Treatment of Colorectal Cancer by Natural Agents from Mother Nature vol.9, pp.1, 2010, https://doi.org/10.1007/s11888-012-0154-1
  2. The differential susceptibilities of MCF-7 and MDA-MB-231 cells to the cytotoxic effects of curcumin are associated with the PI3K/Akt-SKP2-Cip/Kips pathway vol.14, pp.None, 2010, https://doi.org/10.1186/s12935-014-0126-4
  3. Curcumin Suppresses Proliferation of Colon Cancer Cells by Targeting CDK2 vol.7, pp.4, 2010, https://doi.org/10.1158/1940-6207.capr-13-0387
  4. Ruthenium(II) complexes: DNA-binding, cytotoxicity, apoptosis, cellular localization, cell cycle arrest, reactive oxygen species, mitochondrial membrane potential and western blot analysis vol.140, pp.None, 2010, https://doi.org/10.1016/j.jphotobiol.2014.07.011
  5. Natural Health Products (NHP’s) and Natural Compounds as Therapeutic Agents for the Treatment of Cancer; Mechanisms of Anti-Cancer Activity of Natural Compounds and Overall Trends vol.21, pp.22, 2020, https://doi.org/10.3390/ijms21228480
  6. An Update on the Potential Roles of E2F Family Members in Colorectal Cancer vol.13, pp.None, 2010, https://doi.org/10.2147/cmar.s320193
  7. Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids vol.142, pp.None, 2021, https://doi.org/10.1016/j.biopha.2021.112043
  8. Antitumoral Activities of Curcumin and Recent Advances to ImProve Its Oral Bioavailability vol.9, pp.10, 2021, https://doi.org/10.3390/biomedicines9101476